Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
141.7 EUR | -4.90% | -6.31% | -10.06% |
Apr. 24 | IMCD's Spanish Unit to Buy Cobapharma | MT |
Mar. 27 | IMCD's Benelux Arm to Purchase Gova Ingredients | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.46 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.06% | 8.61B | A- | ||
+25.96% | 1.01B | - | ||
+8.23% | 173M | - | - | |
+36.99% | 143M | - | - | |
+4.24% | 115M | - | - | |
-4.88% | 99.64M | - | - | |
+7.15% | 87.9M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IMCD Stock
- Ratings IMCD N.V.